Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?-Reference-Cited by-同舟云学术

Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?

Published:2011-06 Issue:3 Volume:26 Page:273-277
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Dillman Robert O.¹,Barth Neil M.¹,VanderMolen Louis A.¹,Fong Warren H.¹,Mahdavi Khosrow K.¹,McClure Stephanie E.¹

Affiliation:

1. Hoag Cancer Institute, Newport Beach, California.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2011.0969

Reference32 articles.

1. Cancer Statistics, 2010

2. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin-2 chronotherapy for metastatic renal cell carcinoma: Results of a phase I-II study;Cytokine;2020-04

2. The Outcome of Targeted Therapies in Patients with Poor Prognosis Metastatic Renal Cell Carcinoma;Cancer Biotherapy and Radiopharmaceuticals;2014-09

3. The Role of Inflammation in Kidney Cancer;Advances in Experimental Medicine and Biology;2014

4. Immunotherapy and Targeted Therapies in Metastatic Renal Cell Carcinoma: Is There a Preferred Sequence?;Cancer Biotherapy and Radiopharmaceuticals;2012-10

5. Should High-Dose Interleukin-2 Still Be the Preferred Treatment for Patients with Metastatic Melanoma?;Cancer Biotherapy and Radiopharmaceuticals;2012-08